Interest Groups

Health Plans' Limits on Hep C Drug Coverage Leads to Tension - Health Care and Life Sciences News

Get the news you want the way you want it: click the RSS button in the right corner to add this feed to your RSS reader, or click here to subscribe to this content. By subscribing, you’ll find this news on your Member Account page, and the latest articles will be emailed to you in your customized IndyBar E-Bulletin e-newsletter.

Health Care and Life Sciences News

Posted on: Jun 15, 2015

By Alao Mayo, Hall Render Killian Heath & Lyman PC

High price tags for new therapies like Gilead’s Harvoni and Sovaldi and AbbVie’s Viekira Pak are creating tension between payers, providers and now patients. A new lawsuit questions the legitimacy of insurer-imposed restrictions placed on access to these promising new hepatitis C drugs. Read more here

This post was written by Alao Mayo of Hall Render Killian Heath & Lyman PC. If you would like to submit content or write an article for the Health Care and Life Sciences Section page, please email Rachel Beachy at


Indianapolis Bar Association (IndyBar) est. 1878 | 4,536 Members (as of 2.11.21)